Saxenda
Saxenda (liraglutide 3.0mg) is a prescription GLP-1 receptor agonist by Novo Nordisk, administered as a daily subcutaneous injection for chronic weight management. It suppresses appetite by acting on hypothalamic hunger centres and slowing gastric emptying. Indicated for adults with BMI >=30, or >=27 with weight-related comorbidities.
15 分鐘
฿11,500 起
免費諮詢 · 專屬顧問 · 無額外費用
療程效果
- GLP-1 機制作用於大腦飢餓中樞，有效抑制食慾、減少熱量攝取
- 延緩胃排空，延長飽足感，幫助控制飲食份量
- 臨床實證配合飲食運動，12 個月內平均可減重 8 至 10%
- 每日一次皮下自行注射，使用方便
- 獲美國 FDA 及台灣 TFDA 核准用於長期體重管理
- 泰國費用低於歐美，適合在醫療監督下進行減重計畫
適合對象
- BMI≥30 的肥胖成人患者
- BMI≥27 且合併高血壓、第二型糖尿病或血脂異常者
- 曾嘗試飲食及運動控制但效果有限者
- 需要醫療輔助進行系統性體重管理者
- 願意配合長期療程（建議至少 12 週）的患者
- 在泰國正規醫療機構接受醫師評估後進行減重計畫者
注意事項
Prescription medication requiring physician evaluation. Absolutely contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome. Not for use during pregnancy or breastfeeding, or in severe hepatic/renal impairment. Common GI side effects (nausea, vomiting, diarrhoea) typically diminish with gradual dose titration. Rare serious risks include acute pancreatitis and gallbladder disease.
常見問題
Saxenda 適合哪些人？+
Saxenda 療程需要多久？+
Saxenda 在泰國的費用大約多少？+
Saxenda 有哪些注意事項？+
如何透過 BeaVoy 預約 Saxenda？+
你可能也感興趣
MESO FAT
MESO FAT involves micro-injections of phosphatidylcholine (PPC) and deoxycholic acid into the subcutaneous fat layer to break down fat cell membranes, triggering apoptosis. The destroyed cells are then eliminated naturally via the lymphatic system. Best suited for small, localised fat deposits such as the double chin, jowls, arms, and abdomen.
了解更多EMSCULPT
EMSCULPT by BTL uses HIFEM technology to induce 20,000 supramaximal muscle contractions per 30-minute session, simultaneously building muscle and reducing fat without any downtime. Clinical studies show an average 16% increase in muscle mass and 19% reduction in fat after the recommended 4–6 sessions.
了解更多EMSCULPT NEO
EMSCULPT NEO combines HIFEM muscle-stimulation with simultaneous radiofrequency (RF) fat-heating in a single 30-minute session — the world's first such combination device by BTL. It outperforms the original EMSCULPT with clinical averages of 25% muscle increase and 30% fat reduction, and is suitable for patients with BMI up to 35.
了解更多